According to a story by the Daily Record UK, Maggie Ritchie found out she was diagnosed with breast cancer and four years later was successfully cancer-free. She attributed the advanced…
Gene-editing therapies have made almost constant news headlines in relations to cancer treatment. The process of reprogramming the body’s immune cells to fight cancer seems more and more promising. The…
According to a story from Scleroderma News, the results from a recent study suggest that the six minute walk test can accurately predict outcomes for patients with systemic sclerosis. A…
The organisations Guerbet and IBM Watson Health are collaborating to develop an artificial intelligence tool designed to support the diagnosis and care of liver cancer. The source article can be…
A patient with Waldenström Macroglobulinemia taking part in a clinical trial of the experimental drug CLR 131 for the treatment of B-cell hematologic cancers is reported to have achieved a…
According to a story from Hematology Times, a medicine called melflufen, of the alkylating peptide class, appears to be effective in treatment resistant multiple myeloma. In a Phase 2 trial,…
CHICAGO, July 19, 2018 – The Pulmonary Fibrosis Foundation (PFF) and monARC Bionetworks have partnered to create the mobile app, PF Health, for individuals living with pulmonary fibrosis (PF). PF Health, now available on Apple App Store (iOS 9.0 or…
According to a video and article published by Duchenne UK, Professor Steve Winder has been granted additional funds to study the effectiveness of soy as a treatment for Duchenne muscular…
Chronic pain has a sinister way of impacting practically every aspect of our lives. One major area is our social life. Since chronic pain is often misunderstood by others and…
According to a story from PR Newswire, the biopharmaceutical company AbbVie has recently announced that it has sent a supplemental New Drug Application to the FDA for its product venetoclax,…
Clovis Oncology, Inc. has announced that they have submitted an application to the European Medicines Agency (EMA). The application is to extend the drug Rubraca’s®(rucaparib) marketing authorisation to include maintenance…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
